New Ideas.
Better Results.

Blue Matter is a consulting firm serving the life sciences industry. We strive to bring a new approach to consulting with original ideas that deliver a meaningful impact.

Contact Us

Our Purpose

We are proud to be part of an industry that is pushing the boundaries of science and technology to improve people’s lives. Our role is to help our clients identify unique insights, generate new ideas and drive meaningful results to get the most out of their products, portfolios and teams.

We began our careers in established consulting firms where we developed valuable experience and industry knowledge. During this time, we came to see that rigid processes often interfered with original thinking and led to bloated deliverables packed with mediocre answers.

A group of us like-minded, passionate consultants believed there was a better approach and founded Blue Matter to provide a platform to foster innovation and creativity in consulting.

Our Difference

Industry and scientific knowledge, analysis and insights. Left brain thinking. This is the foundation of our discipline. Creativity and imagination. Constantly challenging conventional thinking and seeking fresh ideas. Right brain thinking. We’re passionate about this; it’s the reason our clients come back.

The key to winning is effective differentiation. And effective differentiation comes from originality–thinking that is grounded in reason and infused with imagination.

"The terrific work you did resulted in a substantial change to our commercial strategy."

- Chairman of the Board, Small Biotech

"Thank you very much for the great work and partnership. You are one of the rare breed of consultants whom I trust. You will always be on my speed dial if we need help with anything."

- Chief Commercial Officer, Small Biotech

"I appreciate all of the great work you have done for our team this past year and look forward to continued partnership in the New Year."

- Chief Commercial Officer, Mid-sized Diagnostic Company

"Your preparation and support has been instrumental in achieving our desired outcome."

- Franchise Commercial Lead, Global Biotech

"Thank you all so much for the extremely successful project...I couldn't be happier with the way that it went."

- Sr. Product Manager, Diagnostic Company

"This project was excellent, from the content development to facilitation. Many, many thanks for the great work!"

- Director of Marketing, Diagnostic Company

"The process was great, I loved that I didn't have to manage you that much. Everything was highly organized and done on time. Quality and originality of thinking was also good."

- Global Commercial Lead, Large Biotech

"Great project. I was learning as we went along; good expertise — brought in examples from other projects."

- Global Commercial Lead, Large Biotech

Our Clients

Our clients include: top global bio-pharmaceutical companies with large, diverse product portfolios to small emerging players with one asset in development, leading diagnostic companies, and investment houses. We work with CEOs, Chief Commercial Officers, Franchise Heads, Product Directors, Functional Area Leaders. 90%+ of our business is from repeat, satisfied customers.

Our Services

Shape Innovative Products

Drive Successful Launches

Build Great Portfolios and Companies

Want to Join Our Team?

Blue Matter offers enriching project experiences with a diverse range of strategic, client-facing projects in the exciting and innovative life sciences industry.

Join Our Team

Insights

Follow @BlueMatter1 for info you can use on commercial strategy in #RareDiseases. Here's part 3 in our series on ra… https://t.co/9w2k0KEwb5

Follow @BlueMatter1 for insights on #RareDisease product commercialization. Here's part 2 on our series on rare dis… https://t.co/2kYIIGlcEN

Rare Disease Centers of Excellence

Part III in a Series on Rare Diseases In parts I and II of this series, we provided an overview of the special commercial challenges associated with rare disease (RD) therapies, and we took a deeper dive into one of the most obvious:  Finding patients.   In this installment, we explore rare disease Centers of Excellence … Read More

Finding Patients: A Key Challenge in Rare Diseases

Part 2 in a Series on Rare Diseases Part 1 of this series provided an overview of rare diseases and the special challenges they present to biopharmaceutical companies.  In this installment, we explore one of the most basic—and most confounding—of those challenges:  Finding patients. In the European Union, a disease is considered rare when it … Read More

Blue Matter Academy: Investing in Learning

Blue Matter Academy (BMA) is Blue Matter Consulting’s in-house learning and development organization.  Officially launched in 2017, BMA’s goal is to provide ongoing learning opportunities for all Blue Matter team members.  Recently, Karen Foster, Learning Strategist and Head of Blue Matter Academy, took the time to answer some common questions about the Academy and Blue … Read More

ECRD Vienna 2018 Recap

Recently (10-12 May), we traveled to Vienna to attend the 9th European Conference on Rare Diseases and Orphan Products (ECRD).  In this article, we describe some of the key takeaways from the conference, and the major implications for biopharmaceutical companies operating in this space. Our Focus on Rare Diseases More than 7,000 diseases are classified … Read More

Addressing the Special Commercial Challenges in Rare Diseases

Part 1 in a Series on Rare Diseases In the European Union, a disease is defined as rare when it affects fewer than five in 10,000 people.  In the United States, the definition is similar:  fewer than seven in 10,000 people.1 For the people affected by rare diseases—and the physicians who treat them—the official definition … Read More

Press Release: Blue Matter Announces Key Promotions

FOR IMMEDIATE RELEASE San Francisco, CA – March 19, 2018 – Blue Matter is pleased to announce two key promotions: George Schmidt to Managing Partner and Tom Quirk to Partner. Both are leaders in Blue Matter’s European operation, and have been instrumental in expanding the firm’s presence there. George Schmidt joined Blue Matter in mid-2015 to … Read More

August News Roundup

Blue Matter Consulting is tracking oncology market trends on a daily basis, and looks back each month to highlight the newsworthy events shaping our current and future oncology market landscape. Highly Anticipated Approval Granted for Novartis’ CAR-T Therapy The first CAR-T therapy, tisagenlecleucel (Kymriah) has officially been approved for use in heavily pretreated pediatric patients … Read More